Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 34 of 41.
    «« First « Previous 30  31  32  33  34  35  36  37  38  Next» Last»»
    EudraCT Number: 2010-023062-40 Sponsor Protocol Number: PRP-001 Start Date*: 2011-04-19
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib (BMN 673) in Patients with Advanced or Recurrent Solid Tumors
    Medical condition: Advanced or recurrent solid tumors for which there is no accepted standard treatment or for which standard treatment has failed. Patients may also be eligible if they are unable or decline to unde...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005057-36 Sponsor Protocol Number: GLG-801-07 Start Date*: 2018-05-17
    Sponsor Name:GLG Pharma S.A.
    Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant...
    Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038390 Renal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001702-88 Sponsor Protocol Number: 011-007 Start Date*: 2006-08-07
    Sponsor Name:Novacea, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
    Medical condition: For the treatment of metastatic androgen independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing) HU (Prematurely Ended) CZ (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006195-11 Sponsor Protocol Number: BC1-06 Start Date*: 2008-03-26
    Sponsor Name:Algeta ASA
    Full Title: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
    Medical condition: Hormone refractory prostate cancer with skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027452 Metastases to bone PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) BE (Completed) SK (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005249-21 Sponsor Protocol Number: 1239.3 Start Date*: 2006-02-16
    Sponsor Name:Boehringer Ingelheim Ltd.
    Full Title: A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer
    Medical condition: Chemo-naive hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003618-15 Sponsor Protocol Number: 20321 Start Date*: 2020-06-25
    Sponsor Name:Bayer Consumer Care AG
    Full Title: An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) LT (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) PT (Completed) DE (Trial now transitioned) LV (Trial now transitioned) BG (Trial now transitioned) AT (Completed) EE (Completed) SK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000848-65 Sponsor Protocol Number: 20050244 Start Date*: 2006-09-01
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate...
    Medical condition: Treatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) HU (Completed) GB (Completed) LT (Completed) DE (Completed) SK (Completed) LV (Completed) SE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006543-10 Sponsor Protocol Number: XB002-101 Start Date*: 2023-03-27
    Sponsor Name:Exelixis, Inc.
    Full Title: A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors
    Medical condition: Advanced solid tumors for whom life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. Single-agent XB002 will be evaluated up to 10 tumor types, and c...
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083234 Hormone receptor positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030151 Oesophageal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084066 Triple negative breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002164-13 Sponsor Protocol Number: UZBRU_VHH1_3 Start Date*: 2017-01-05
    Sponsor Name:UZ Brussel
    Full Title: Quantification of 68GaNOTA-Anti-HER2 VHH1 Uptake in metastasis of Breast carcinoma and cancer patients and Assessment of Repeatability – Pilot study
    Medical condition: Breast cancer; salivary gland cancer; adenocarcinoma of the gastric body or gastro-esophageal junction; endometrial cancer; cancer of cervix uteri; Non-small cell lung cancer; biliary tract cancer;...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019862-10 Sponsor Protocol Number: A-93-52030-738 Start Date*: 2010-12-06
    Sponsor Name:IPSEN
    Full Title: Randomised, phase III multicenter, open study of lanreotide in non metastatic castration-resistant prostate cancer patients presenting elevated Chromogranin A levels
    Medical condition: Patients with prostate cancer presenting Neuro-Endocrine (NE) differentiation developing non metatstatic castrate resistant disease and eligible to second line hormone treatment with non steroidal ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029104 SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000931-15 Sponsor Protocol Number: ICR-CTSU/2016/10060 Start Date*: 2018-07-02
    Sponsor Name:Institute of Cancer Research
    Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000744-10 Sponsor Protocol Number: P.64Cu.003.01 Start Date*: 2019-06-28
    Sponsor Name:A.C.O.M. -ADVANCED CENTER ONCOLOGY MACERATA -S.R.L.
    Full Title: Higher diagnostic accuracy of 64Cu PET/CT compared to standard 18F-choline PET/CT in the detection rate of metastasis from prostate cancer. Phase III multicenter, sponsored, interventional "open-la...
    Medical condition: Prostate cancer at risk of developing metastatic lesions
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002605-65 Sponsor Protocol Number: DOTA2013/DOTATER Start Date*: 2013-11-26
    Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS
    Full Title: Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors.
    Medical condition: Patients with tumors expressing somatostatin receptors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004484-39 Sponsor Protocol Number: BAY1895344/18594 Start Date*: 2017-07-18
    Sponsor Name:Bayer AG
    Full Title: An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the A...
    Medical condition: Part A+A.1: Histologically confirmed solid tumors or NHL Part A J-arm : Advanced solid tumors Part B: a) DDR deficient advanced solid tumors: i) CRPC; ii) HER2- negative BC (estrogen-receptor posit...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004319-20 Sponsor Protocol Number: 55218 Start Date*: 2017-06-29
    Sponsor Name:Maasstad Ziekenhuis
    Full Title: Spinal Morphine in Robotic Assisted Radical Prostatectomy
    Medical condition: Robotic Assisted Radical Prostatectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002735-16 Sponsor Protocol Number: ABI-STAR-2016 Start Date*: 2016-12-13
    Sponsor Name:Otto-von-Guericke-Universität Magdeburg
    Full Title: Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®)
    Medical condition: metastatic castration-resistant prostate carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001358-24 Sponsor Protocol Number: B9991040 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Bempegaldesleukin (NKTR-214) with or without Talazoparib or Enzalutamide in Participants with Locally Adv...
    Medical condition: Locally recurrent (not amenable for curative intent) or metastatic squamous cell carcinoma of the of the oral cavity, oropharynx, hypopharynx, or larynx; metastatic castration-resistant prostate...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006712-93 Sponsor Protocol Number: MK-1088-002 Start Date*: 2022-06-09
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
    Medical condition: Advanced/metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2004-001347-29 Sponsor Protocol Number: Start Date*: 2004-09-17
    Sponsor Name:Odense University Hospital
    Full Title: Treatment of patients with locally advanced rectal cancer. TEGAFOX (UFT/leukovorin og Oxaliplatin) before, during and after curatively intended radiotherapy. A Danish phase I/II trial
    Medical condition: Locally advanced non-resectable rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    6.0 10038050 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005110-34 Sponsor Protocol Number: ICT01-102 Start Date*: 2022-02-08
    Sponsor Name:ImCheck Therapeutics, Inc.
    Full Title: A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advance...
    Medical condition: Relapsed/refractory patients with advanced solid tumors : metastatic colorectal cancer (CRC) or metastatic ovarian cancer or metastatic castration-resistant prostate cancer (mCRPC) or metastatic pa...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 30  31  32  33  34  35  36  37  38  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 15:53:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA